<< Previous Story----Next Story >>

LONDON -(Dow Jones)- GlaxoSmithKline PLC (GSK) Wednesday said its experimental pediatric vaccine Synflorix should offer protection for children against most pneumococcal diseases, citing data from a late-stage study.

The vaccine - which protects against most major strains of streptococcus pneumoniae, the bacteria responsible for diseases like meningitis, pneumonia and ear infections - was filed for regulatory review with the European Medicines Agency in January.

The data, presented at a scientific meeting in Reykjavik, Iceland, showed that Synflorix elicited a strong antibody response for the 10 strains of streptococcus pneumoniae it targets.

If successfully launched into the market, Synflorix would compete against Wyeth's (WYE) blockbuster pediatric vaccine Prevnar, which targets seven of the most prevalent pneumococcus strains.

Company Web site: www.gsk.com

<< Previous Story----Next Story >>